Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Why LinkedIn Isn’t Effective in Japan
August 27, 2024
- The Dynamics of Field Medical Visits: Importance of Balancing Quality and Frequency in Medical Interactions
August 2, 2024
- 3 Common Mistakes Made when Hiring a Leader
July 25, 2024
- 3 Tips for Establishing Local Connections in Japan
June 28, 2024
- How to Plan for Future Talent Needs
May 31, 2024
- Boosting Employee Retention in a Competitive Market
April 18, 2024
- How to Paint an Irresistible Picture of Success
March 22, 2024
- Positioning Your Company as an Employer of Choice
February 22, 2024
- Navigating the Evolving Landscape of Medical Affairs: Integrating Insights and Identity for Future Success
February 7, 2024
- How NOT to Write a Job Description
January 26, 2024
- Goal-Setting for 2024: Crushing It
December 20, 2023
- The Power of Referrals and Who to Ask
November 24, 2023
- How Can Innovative Field Force Roles and Ways of Working Create More Impactful Engagement?
November 2, 2023
- 3 Strategies for Attracting Talent Who Aren’t Looking for a Job
October 18, 2023
- How Can You Improve Field Force Productivity in the Age of Digital? Omnichannel Excellence and the Importance of a Strong “Middle Layer”
October 6, 2023
- How to Get 4 Qualified Candidates within 4 Weeks
September 25, 2023
- How Far Has Your Organization Come? Key Lessons Learned from Ongoing Commercial Transformations in Japan
September 11, 2023
- Mission Impossible: Finding the Right Leader to Launch a Disruptive Medical Technology into Japan
August 10, 2023
- How Healthcare Companies Should Hire in the Post-COVID Work Environment
July 19, 2023
- The Impact of a Shrinking Labor Market on the Healthcare Industry
June 23, 2023
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…